Global Infectious Disease Drug Market: Strategic Assessments of Leading Suppliers

Oct. 12, 2011 - PRLog -- Venture Planning Group (www.VPGMarketResearch.com), an international publishing and management consulting firm, is pleased to announce the completion of a new 1,353-page report, "Global Infectious Disease Drug Market: Strategic Assessments of Leading Suppliers." (http://www.vpgmarketresearch.com/ethical-pharmaceuticals.html). The report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Infectious Disease Drug Market.

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Infectious Disease Drug Market.

The report provides a worldwide strategic overview of the pharmaceutical market, including:

•Sales forecast for major product segments: ethical, OTC, generics.
•Sales forecast for major drug categories.
•Sales forecasts by geographical region: North America, Europe, Japan, Latin America.

In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies.

The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.

The report’s major objectives include:

•To establish a comprehensive, factual, annually updated and cost-effective information based on performance, capabilities, goals and strategies of the leading players in the global infectious disease drug market.
•To help current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis the leading competitors.
•To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
•To complement organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight.

Contains 1,353 pages and 127 tables

To review or order this report, please visit
http://www.vpgmarketresearch.com/Global-Infectious-Diseas...

To review related reports, please visit
http://www.VPGMarketResearch.com

Contact
Robert Fisher
robert@vpgcorp.com
+1 212 564 2838

# # #

Venture Planning Group is an international market research, publishing and management consulting firm, providing syndicated and custom services to corporate executives and key decision-makers in the Diagnostics, Pharmaceutical, Imaging, Orthopedics, Biotechnology, Chemical, Flavors & Fragrances, Food & Beverage, Electronics, and other industries.

During numerous proprietary single-client consulting assignments and over 500 multiclient studies, VPG has developed an extensive database on various industries, technologies, markets, companies, products, and executives worldwide.

VPG has served over 1,000 corporations in 70 countries, and has established a broad network of worldwide contacts with industry executives, opinion leaders, and experts from leading universities, research centers, the financial community and the government.

Specialties
Market Intelligence Surveys, Opportunity Analyses, New Technology/Product Assessments, Acquisition/Joint Venture Evaluations.